Articles

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

Department of Hematology, Cliniques Universitaires Saint-Luc, UCL Brussels, Belgium
Hematology Department, CHU UCL Namur, Yvoir, Belgium
Hematology, CHU Nantes, France
Clinical Hematology, Centre Henri Becquerel, Rouen, France
Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Mondor, Créteil, France
Onco-hematology, Centre Leon Berard, University Claude Bernard Lyon 1, France
Hematology, Centre Hospitalier Universitaire, Caen, France
Hematology Department, Hopital Le Bocage, CHU Dijon, France
Hospices Civils de Lyon, Université Claude Bernard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France
Department of Hematology, University Hospitals Leuven, Belgium
Erasmus MC, Rotterdam, the Netherlands
Center for Human Genetics, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
CHRU de Lille, France
CHRU de Lille, France
Center for Human Genetics, Katholieke Universiteit - Leuven, Belgium
Nuclear Medicine, Cliniques Universitaires Saint-Luc, UCL Brussels, Belgium
Nuclear Medicine, Hôpital Tenon, Paris, France
Department of Hematology, Cliniques Universitaires Saint-Luc, UCL Brussels, Belgium
Cliniques Universitaires Saint-Luc and de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
CHU Lille, Hematology Department, and Université de Lille, GRITA, France
Vol. 103 No. 5 (2018): May, 2018 https://doi.org/10.3324/haematol.2017.180554